Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce that the Company attended the 15th World ADC San Diego from 4–7 November 2024, the world’s leading and longest-standing forum on antibody-drug conjugates (ADCs).
- 0 Comments
- FY2024